利格列汀联合二甲双胍及磺脲类药物在2型糖尿病患者治疗中有效性、安全性分析

摘要

Objective Effectiveness and safety in patients with type 2 diabetes (metformin and sulfonylurea poor glycemic control) related data of sitagliptin and metformin and sulfonylurea therapy. Method 48 cases of type 2 diabetic patients were randomly divided into profit according to the proportion of 2:1 sitagliptin group and the placebo group, the two groups were treated for 24 weeks. Results Glenn dean with metformin or sulfonylureas hypoglycemic drugs combined use of 24 weeks can significantly reduce glycated hemoglobin (HbA1c) level (compared with the placebo group, HbA1c down 0.62%, compared with baseline (P<0.0001). Conclusion the Glenn dean with metformin or sulfonylureas hypoglycemic drugs combined use of safe and ef ective.%目的：：研究利格列汀联合二甲双胍及磺脲类降糖药物治疗（二甲双胍及磺脲类药物血糖控制不佳的）的2型糖尿病患者有效性及安全性的相关数据。方法：48例2型糖尿病患者按2：1比例随机分为利格列汀组与安慰剂组，两组均用药24周。结果：利格列汀与二甲双胍及磺脲类降糖药物联合应用24周可以显著降低糖化血红蛋白（HbA1c）的水平（与安慰剂组比较，HbA1c较基线时下降0.62%，P＜0.0001）。结论：利格列汀与二甲双胍及磺脲类降糖药物联合应用安全有效。